By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Amgen (AMGN)'s Xgeva Meets Primary Endpoints in Late-Stage Study, Secondary Endpoints Missed 10/21/2016 6:13:58 AM
Amgen (AMGN) Announces Appointment Of Ellen J. Kullman To Board Of Directors 10/17/2016 8:19:16 AM
Amgen (AMGN) Announces 2016 Fourth Quarter Dividend 10/17/2016 8:18:01 AM
Why Amgen (AMGN), Biogen (BIIB) and Celgene (CELG) are the Best Biotech Stocks Now 10/11/2016 6:52:58 AM
Amgen (AMGN) Release: New Retrospective Analyses Confirm Vectibix (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin 10/10/2016 7:26:46 AM
Amgen (AMGN) Rumored to be Quietly Rehiring Employees for Its Shuttered Colorado Facility 10/10/2016 6:09:06 AM
New Amgen (AMGN) Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress 10/6/2016 8:46:18 AM
Amgen (AMGN) To Participate In Citi Biotech R&D Conference Call 10/5/2016 8:54:38 AM
Amgen (AMGN) Release: Study Results Published In Journal Of Clinical Oncology Show BLINCYTO (Blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 10/4/2016 7:16:49 AM
Biotech Giant Amgen (AMGN) Forges $410 Million R&D Pact With Tiny Nuevolution 10/4/2016 6:05:59 AM